Answer from: Radiation Oncologist at Academic Institution
The EF14 trial included newly diagnosed glioblastoma patients who had gross total resections and those who had biopsies. Only 54% of patients had a GTR and 13% had biopsy. TTF plus temzolomide was associated with an increase in PFS and OS in all subgroups including...